84 results about "Apolipoproteins b" patented technology

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.

Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

The present invention provides nucleic acid-lipid particles comprising siRNA molecules that silence ApoB expression and methods of using such nucleic acid-lipid particles to silence ApoB expression.

Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.

Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided.

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.

Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.

Methods for the rapid and long-term lowering of lipid levels in human subjects and for the treatment of conditions associated with elevated LDL-cholesterol and elevated apolipoprotein B are provided.

The invention provides a human blood fat (serum / plasma) quality management reference kit. The kit takes human serum (plasma) as a matrix; a human blood fat component (human apolipoprotein A1 antigen, apolipoprotein B antigen, high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL) and the like), a stable system and an anticorrosion system are added to the matrix; the stable system is any combination of a surfactant of Triton series, Tween series, EDTA (ethylene diamine tetraacetic acid) series and the like, a polymer of polyvinyl alcohol series, polyvinylpyrrolidone series, polyethylene glycol series and the like, and a phosphate buffer solution; and the anticorrosion system is any combination of sodium azide, gentamicin, amphomycin and ProClin series. The invention further provides a preparation method of the kit. The kit is free from medium effect interference, is used for quality control and evaluation between the detection systems, and more really reflects actual quality conditions of human serum (plasma) samples, which are detected by detection systems.

The present invention relates to a fragment of apolipoprotein B, for immunization for prophylactic or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, in particular myocardial infarction or stroke, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing ischemic cardiovascular diseases including stroke, using said peptide in an assay, pharmaceutical compositions comprising the peptide. The invention further encompasses a particular peptide sequence aggravating disease, which sequence then can be used for diagnostic assays.

The invention discloses a stable liquid lipid calibrator which comprises 20-200mmol / L of buffer liquid, 2-10% (w / v) of protein stabilizer, 110-200mmol / L of electrolyte NaC, 5-100mmol / L of anti-oxidation synergist, 10-100g / L of sugar stabilizer, 0.09% (w / v) of preservative, 0.02-100mmpl / L of antioxidant, 0.1-5mmol / L of protease inhibitor, 2.0-3.0g / L of apolipoprotein A-I and 2-2.5g / L of apolipoprotein B. By adopting the stable liquid lipid calibrator, the stability of the apolipoprotein A-I and the apolipoprotein B is effectively improved, the apolipoprotein A-I and the apolipoprotein B can be stably frozen at 2-8 DEG C for one year and are relatively convenient and efficient to use and preserve, and the accuracy in measuring the contents of the apolipoprotein A-I and apolipoprotein B in a sample is improved.

Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.

The invention discloses a preparation method for a calibration matter for calibrating apolipoprotein A1 and apolipoprotein B. The essentials of the technical scheme are as follows: the preparation method comprises the following steps: (1) adding a multi-anionic compound and divalent metal ions into blood serum to carry out pre-treatment; (2) extracting low density lipoprotein (LDL); (3) extracting high density lipoprotein (HDL); (4) mixing protein and base blood serum to prepare the calibration matter; (5) defining the value of the calibration matter. The preparation method has the advantages that the extraction of LDL and HDL components in the blood serum by a multi-anionic compound and divalent metal ion sub-step precipitation method is simplified; the content of the ApoB and the content of the ApoA1 are detected; the calibration matter can be mixed into the blood serum of healthy people according to the needed amount so that the ApoA1 and the ApoB reach the predicated content; the method is simple; a stabilizer and a turbidity-preventing agent are added into the mixed blood serum so that the prepared freeze-dried calibration matter is clarified after being re-dissolved; the stability is good and a base material effect does not exist; the calibration matter is diluted into five different concentrations and can be used for non-linear calibration of determining the ApoA1 and the ApoB on an automatic analyzer.

The present invention provides compositions and methods for the delivery of interfering RNAs that silence APOB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

This application discloses a quality control substance for a blood lipid test. Specifically, a disclosed composition comprises serum matrix, protective agent, preservative, total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol, apolipoprotein A1, apolipoprotein B, lipoprotein (a), optional apolipoprotein E, optional phospholipid, optional homocysteine, optional C-reactive protein, and optional small and low density lipoprotein cholesterol. The application also relates to the use of this combination in the preparation of quality control substances. The quality control substance according to this application has excellent uniformity in and between bottles, while maintaining good stability.

The invention discloses a kit used for detecting susceptibility to femoral head necrosis. The kit detects six genes which have close relation with the femoral head necrosis, namely a vascular endothelial growth factor (VEGF) gene of vascular endothelial factors, a coagulation factor V (FV) gene of coagulation factors, a methylene tetrahydrofolate reductase (MTHFR) gene, a pamoxonase 1 (PON1) gene of lipid metabolism related gene, an apolipoprotein A1 (APOA1) gene and an apolipoprotein B (APOB) gene. The kit detects a group of genes and loci related to the susceptibility to the femoral head necrosis through specific primers and probes by combining a single nucleotide extension technology with a microarray chip technology, can clearly judge whether examinees carry femoral head necrosis susceptibility genes and screens a group susceptible to the femoral head necrosis from the examinees, so as to make the group change bad living habits and fulfill the aim of preventing the femoral head necrosis.

The present invention relates to a fragment of apolipoprotein B, for immunization for prophylactic or therapeutic treatment of mammals, including humans, against ischemic cardiovascular diseases, in particular myocardial infarction or stroke, as well as diagnosing the presence or absence of antibodies related to increased or decreased risk of developing ischemic cardiovascular diseases including stroke, using said peptide in an assay, pharmaceutical compositions comprising the peptide. The invention further encompasses a particular peptide sequence aggravating disease, which sequence then can be used for diagnostic assays.

The present invention relates to an improved method for the isolation of high density lipoprotein (HDL) or HDL-like particles. The method of the present invention provides for the isolation of a more highly purified HDL that requires substantially less time than standard methods. The present invention relates to an improved method for the isolation of high density lipoprotein or HDL-like particles comprising the steps of precipitation of apoprotein B-containing proteins and a single ultracentrifugation to recover high density lipoprotein or HDL-like particles.

The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells such as liver cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.

The invention discloses a construction method of a gene detection library of familial hypercholesterolemia and a gene detection kit and relates to gene mutation of LDLR (Low-Density Lipoprotein Receptor), APOB (Apolipoprotein B) and PCSK9 (Proprotein Convertase Subtilisin / Kexin type 9). In order to ensure that all target regions (including an entire coding region and an alternative splicing regionof a gene to be detected) are covered and prevent a primer dimer or a short segment from being formed between primers of adjacent amplicons, a PCR (Polymerase Chain Reaction) amplification primer isdivided into two independent primer pools; then primer sequence digestion, sequencing connector connection, library purification and quality detection are carried out; finally, the detection library is constructed. The method has the advantages that library establishment steps are simple and rapid, the cost is effectively reduced, the working amount is reduced, variation types are comprehensive, the detection accuracy reaches 100 percent and the flux is high.

The invention discloses a kit for genetic detection of diabetes. The kit comprises a specific primer pair and a specific probe pair which are used for detecting the mononucleotide polymorphism loci genotype of an apolipoprotein B gene (APOB), a leptin gene (LEP), a lipoprotein lipase gene (LPL) and an uncoupling protein 2 gene (UCP2), a fluorescent quantitative PCR general component and the like. The kit can evaluate the genetic risk of individuals suffered from the obesity by detecting the polymorphism loci genotype of the genes closely related to the genetic risk of the obesity at the same time.

The invention discloses an apoB gene SNP (Single Nucleotide Polymorphism) detection specific primer and liquid-phase chip. The liquid-phase chip comprises an ASPE (Allele Specific Primer Extension) primer, microspheres and an amplification primer, wherein the ASPE primer consists of a tag sequence at 5' end and specific primers aiming at target gene mutation at 3' end, wherein the specific primers are SEQ ID NO. 12 and SEQ ID NO. 13 aiming at a C181T SNP site, SEQ ID NO. 14 and SEQ ID NO. 15 aiming at a C245A SNP site, SEQ ID NO. 14 and SEQ ID NO. 15 aiming at a C245T SNP site, SEQ ID NO. 17 and SEQ ID NO. 18 aiming at a G153A SNP site, SEQ ID NO. 19 and SEQ ID NO. 20 aiming at a G82A SNP site, and / or SEQ ID NO. 21 and SEQ ID NO. 22 aiming at a G62A SNP site; and the microspheres are coated by anti-tag sequence. The matching ratio of the detection result of the apoB gene SNP detection liquid-phase chip provided by the invention and that of a sequencing method reaches up to 100 percent; and parallel detection of a plurality of polymorphic sites is realized.

The invention discloses a method for producing anti-apolipoprotein B (ApoB) multi-antibody serum by using a Zhejiang sheep. The method comprises the following steps: preparing immunogenic original emulsion, selecting the Zhejiang sheep to perform immunization for four times, and the like, wherein the groin and the sole of the Zhejiang sheep are selected to inject during the immunization; finally collecting the blood and separating the serum. The titer of the multi-antibody serum which is finally produced by the production method is 1:512; the multi-antibody serum has high benefit.

The use of Apolipoprotein B, Apolipoprotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications In prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathics and other prion diseases.

Disclosed herein are compositions and methods for lowering Apolipoprotein C-III (ApoC-III) in a subject in need thereof. Subjects in need of ApoC-III reduction include subjects with elevated ApoC-III levels, subjects with a condition associated with ApoC-III, subjects with diabetes, obese subjects and subjects with cardiovascular disease. Compositions to lower ApoC-III include compounds targeting Apolipoprotein B (ApoB) such as Mipomersen and other antisense compound targeting ApoB.

The invention provides a Chinese herbal compound for treating the pubertal polycystic ovary syndrome. The Chinese herbal compound is prepared from, by weight, 30-35 parts of radix astragali, 20-25 parts of American ginseng, 15-20 parts of Radix Salviae Miltiorrhizae,, 15-20 parts of hawthorn, 15-20 parts of poria cocos, 20-25 parts of bighead atractylodes rhizome and 15-20 parts of tangerine peel. The pubertal polycystic ovary syndrome (PCOS) is treated through the method of tonifying qi and spleens, reducing phlegm, activating blood and regulating constitution; compared with other traditional Chinese medicine research, the Chinese herbal compound can reduce levels of luteinizing hormone (LH), luteinizing hormone / follicle-stimulating hormone (LH / FSH), testosterone (T) and androstenedione (AND) in serum of patients and also can reduce the levels of total cholesterol (TC) and apolipoprotein B (APOB) in blood fat, and therefore the aims of regulating the menstrual cycle, improving hyperandrogenism and correcting dyslipidemia are achieved.

Belonging to the field of pharmacy, the invention relates to application of a Chinese prickly ash extract to preparation of medicaments for regulating cholesterol metabolism. In particular, the invention relates to regulation of cholesterol metabolism by a petroleum ether extract, an ethyl acetate extract and an n-butanol extract in high cholesterol and inflammation states. In vitro experiments show that in high cholesterol condition, the extracts can reduce the content of total cholesterol and secretion of an apolipoprotein B, inhibit the expression of related genes and proteins in a cholesterol biosynthesis pathway in cells, increase the expression of related genes or proteins in a reverse cholesterol transport process in cells. In vivo experiments prove that the ethyl acetate extract and n-butanol extract have anti-inflammatory activity, and improve the accumulation of inflammation-induced cholesterol in the liver by affecting expression of a liver X receptor-alpha and an ATP-binding cassette transporter gene 1. The invention further provides monomer (-)-syringaresinol-4-O-beta-D-glucoside isolated from the n-butanol extract and application thereof to regulation of cholesterol metabolism.